Bandi Parthasaradhi Reddy – Chairman & Managing Director, Hetero…
Since the company’s foundation in 1993, Hetero has clearly come a long way. What were the key success factors at that time, which laid the groundwork of a successful company?…
Address: HETERO DRUGS LIMITED, 7-2-A2, HETERO CORPORATE, INDUSTRIAL ESTATES. SANATH NAGAR, HYDERABAD – 500 018. A.P. INDIA
,India
Tel: +91 40 23704923
Hetero is a research based global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & Finished Dosages. Ever since its establishment in 1993, Hetero showed a tradition of excellence and deep sense of commitment in developing cost effective processes to offer wide range of affordable drugs.
Hetero is building on the strengths of vertical integration in discovery research, process chemistry, API manufacturing, formulation development and commercialization. Hetero is a leading international supplier with a rich portfolio of over 200 products from wide range of therapeutic categories both in active pharmaceutical ingredients and finished dosages.
Hetero’s manufacturing facilities are cGMP compliant meeting global standards in terms of infrastructure and systems. Majority of them are approved by the various regulatory authorities of USFDA, WHO-Geneva, Australian TGA, Spanish agency of medicines & health care products, ANVISA-Brazil, IDA-Netherlands etc.,
With full-fledged marketing capabilities, the company has been able to market its products in over 138 countries across the globe.
APIs
Hetero is one of the largest manufacturer and supplier of Active Pharmaceutical Ingredients (API’s) catering to the ever increasing requirements of the global pharmaceutical market.
The infrastructure available with Hetero for manufacturing of Active Pharmaceutical Ingredients and the intermediate chemicals is one of the best, with State-of-the- Art facilities designed to meet the global standards and cGMPs.
With 11 API manufacturing facilities in operation, Hetero has been able to manufacture more than 200 APIs, and supply to different markets. 6 of the API facilities are approved by USFDA, TGA, EU, PMDA, KFDA and WHO.
Hetero is a trusted supplier of several APIs in wide range of therapeutic categories and the largest supplier of complete range in Antiretroviral products.
Hetero also has dedicated facility for manufacturing of Oncology products.
FINISHED DOSAGES
Hetero has world-class facilities for manufacturing wide range of finished dosages.
As a leading innovation-driven corporation, Hetero is developing a growing portfolio of pharmaceutical products to meet some of the world’s most urgent medical needs. Today Hetero is manufacturing product portfolio of over 200 products in major therapeutic areas, with an emphasis on antiretroviral, gastro-intestinal, cardiovascular, antidepressants/antipsychotics, antidiabetics, pain management, anti-infectives, dermatology and oncology. Hetero has
Four finished dosage manufacturing facilities, out of which two are USFDA approved facilities.
Dedicated Oncology facility
Offers
Injectables
Solid/Liquid oral dosages
Ointments
Soft gelatine capsules
Inhalers
INTERMEDIATE CHEMICALS
For information on intermediate chemicals please contact:
uma@heterodrugs.com
contact@heterodrugs.com
CRAMS
Hetero initiated customer-centric division that will provide Custom Research And Manufacturing Services (CRAMS) for large, mid-sized and emerging biotech and pharmaceutical entities globally.
Hetero will partner with these companies and cultivate opportunities to research, manufacture and develop compounds across the entire drug life cycle. This division will deliver fully-consolidated or customized manufacturing solutions for APIs, intermediate chemicals, pre-formulations and formulations across each stage of the pharmaceutical life cycle. Hetero provides premium solutions for product life cycle management including life cycle extensions and line extensions.
BIOTECHNOLOGY
Hetero is focusing on the development and manufacturing of bio-generics for domestic and international markets.
Product Pipeline
Five biosimilars are in the various stages of development. Two products are expected to be commercialized in India for oncology and nephrology indications by 2011-12.
DRUG DISCOVERY
Hetero started discovery research with the focus on developing NCEs in selected therapeutic areas. Scientists at Drug Discovery Division are working on the following projects :
ANTI-HIV Research
ANTI-HCV Research
Diabetes Research
Our business strategy is to out licence early stage discovery molecules and to explore early stage discovery collaborations to maximize the potential of our discovery projects.
Since the company’s foundation in 1993, Hetero has clearly come a long way. What were the key success factors at that time, which laid the groundwork of a successful company?…
Sanjay Bhutani of Bausch & Lomb outlines why the medical devices sector in India is poised for substantial growth, bolstered by increased government support and a higher healthcare budget. He…
Regular contributor Brendan Shaw gives his informed take on how best international stakeholders can engage with India’s attempts to transform into a global pharma innovation powerhouse, Our greatest ability…
Dr Santosh Indraksha serves as Deputy Drugs Controller (India) for the Central Drugs Standard Control Organisation (CDSCO) under the Indian Ministry of Health and Family Welfare. As a representative of…
Clinical trials will be a pivotal part of India’s attempts to scale the global pharmaceutical value chain. Following a series of well-publicised scandals in the early 2010s, the country tightened…
Dr Viranchi Shah of Saga Lifesciences and the Indian Drug Manufacturers Association (IDMA) outlines the Indian pharmaceutical industry’s potential for growth and its role in global health initiatives. He highlights…
Drawing on a unique background in both medicine and law, Dr Milind Antani today leads the pharma and healthcare practice at Nishith Desai Associates, covering everything from regulatory work to…
J&J India’s Jayashri Kulkarni lays out her approach to comprehensive leadership, drawing on her diverse career history across various sectors; her mandate to leverage innovative assets to transform disease management…
Shailesh Siroya explains the rationale behind Bal Pharma’s strategic focus on niche products within the API segment, avoiding the broader, more competitive commodity markets and enabling it to establish a…
Multinational life science firms have been present in India for decades. However, they have often eschewed bringing their latest products to a country that has long prioritised affordability above innovation.…
Under the leadership of Ajay Tandon and the foundational work of Dr Kiran Marthak, Indian firm Veeda Clinical Research has strategically expanded its capabilities and global footprint. The company has…
Sampada Gosavi explains how she has led a transformation of Astellas’ operations in India to launch innovative products in oncology and women’s health, coupled with a commitment to building internal…
Girisan Kariangal reflects on Menarini’s journey from a primarily CSO organization to a robust branded business in India, emphasizing strategic partnerships, acquisitions, and a decisive shift towards dermatology. He outlines…
See our Cookie Privacy Policy Here
